World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
28751
World Ranking
15497
National Ranking
7812

Overview

Filip Janku is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with significant contributions in Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research, and Genetics.

Their work covers a broad spectrum of topics, including:

  • Cancer Genomics and Diagnostics
  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Cancer Research and Treatments
  • PI3K/AKT/mTOR signaling in cancer
  • Colorectal Cancer Treatments and Studies
  • Cancer-related Molecular Pathways

Frequent coauthors in their research include Funda Meric-Bernstam, Sarina A. Piha-Paul, David S. Hong, Apostolia M. Tsimberidou, and Aung Naing, reflecting collaboration across multiple studies.

Filip Janku has published extensively, with numerous articles appearing in key scientific journals. Predominant venues for their work are:

  • Journal of Clinical Oncology
  • Cancer Research
  • Annals of Oncology
  • Regular and Young Investigator Award Abstracts
  • Clinical Cancer Research

Selected recent papers authored or coauthored by Filip Janku include:

  • Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era, 2020, Blood
  • Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma, 2020, Journal of Clinical Oncology
  • Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial, 2021, Clinical Cancer Research
  • Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma, 2020, Journal of Clinical Oncology
  • Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors, 2020, Clinical Cancer Research

Best Publications

  • Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.

    Jean-François Emile;Oussama Abla;Sylvie Fraitag;Annacarin Horne

  • Targeting the PI3K pathway in cancer: are we making headway?

    Filip Janku;Timothy A. Yap;Funda Meric-Bernstam

  • Autophagy as a target for anticancer therapy

    Filip Janku;David J. McConkey;David S. Hong;Razelle Kurzrock

  • Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.

    Scott Kopetz;Jayesh Desai;Emily Chan;Joel Randolph Hecht

  • Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease

    Eli L. Diamond;Lorenzo Dagna;David M. Hyman;Giulio Cavalli

  • Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

    Apostolia M. Tsimberidou;Nancy G. Iskander;David S. Hong;Jennifer J. Wheler

  • PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations

    Filip Janku;Jennifer J. Wheler;Shannon N. Westin;Stacy L. Moulder

  • Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

    Eli L. Diamond;Benjamin H. Durham;Julien Haroche;Zhan Yao

  • Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications

    Chaitanya R. Churi;Rachna Shroff;Ying Wang;Asif Rashid

  • Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials

    Funda Meric-Bernstam;Lauren Brusco;Kenna Shaw;Chacha Horombe

  • PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

    Filip Janku;Apostolia Maria Tsimberidou;Ignacio Garrido-Laguna;Xuemei Wang

  • A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

    Philippe L. Bedard;Josep Tabernero;Filip Janku;Zev A. Wainberg

  • Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses

    Nicholas J. Roberts;Linping Zhang;Filip Janku;Amanda Collins

  • Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

    Dejan Juric;Jordi Rodon;Josep Tabernero;Filip Janku

  • First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

    Ryan J. Sullivan;Jeffrey R. Infante;Filip Janku;Deborah Jean Lee Wong

  • Targeted therapy in non-small-cell lung cancer—is it becoming a reality?

    Filip Janku;David J. Stewart;Razelle Kurzrock

  • PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials

    Filip Janku;Jennifer J. Wheler;Aung Naing;Gerald S. Falchook

  • Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

    Gaurav Goyal;Mark L. Heaney;Matthew Collin;Matthew Collin;Fleur Cohen-Aubart

  • Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

    Filip Janku;David S. Hong;Siqing Fu;Sarina A. Piha-Paul

  • Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment

    M. P. Morelli;M. J. Overman;A. Dasari;S. M.A. Kazmi

Frequent Co-Authors

David S. Hong
David S. Hong The University of Texas MD Anderson Cancer Center
Sarina Anne Piha-Paul
Sarina Anne Piha-Paul The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
Funda Meric-Bernstam The University of Texas MD Anderson Cancer Center
Apostolia Maria Tsimberidou
Apostolia Maria Tsimberidou The University of Texas MD Anderson Cancer Center
Razelle Kurzrock
Razelle Kurzrock Medical College of Wisconsin
Kenneth R. Hess
Kenneth R. Hess The University of Texas MD Anderson Cancer Center
Rajyalakshmi Luthra
Rajyalakshmi Luthra The University of Texas MD Anderson Cancer Center
Scott Kopetz
Scott Kopetz The University of Texas MD Anderson Cancer Center
Michael J. Overman
Michael J. Overman The University of Texas MD Anderson Cancer Center
Milind Javle
Milind Javle The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in careers beyond traditional medical practice, a variety of related online degrees offer alternative pathways within healthcare. For example, earning a bachelors in health administration can open doors to management and leadership roles in hospitals, clinics, and long-term care facilities.

Advancing with a graduate degree, students often consider a Master of Healthcare Administration (MHA). Factors such as mha degree cost play a critical role in decision-making, with affordable online options making this career step more accessible.

Nurses aiming for leadership or advanced clinical positions may pursue terminal degrees. Researching the least expensive dnp programs online can help registered nurses become nurse practitioners or nurse executives at a lower financial burden.

Pharmacy professionals are also turning to online doctorates. Those who want to become pharmacists can explore online pharmd programs that provide flexibility and affordability.

Ultimately, whether you are interested in administration, nursing, or pharmacy, online degrees can offer diverse, cost-effective paths toward a rewarding healthcare career.

Best Scientists Citing Filip Janku

Trending Scientists

Recently Published Articles